Pfizer
Clinical trials sponsored by Pfizer, explained in plain language.
-
Pfizer tests Next-Gen baby vaccine against Pneumonia-Causing germs
⭐️ VACCINE ⭐️ OngoingThis study is testing a new experimental vaccine designed to protect infants against pneumococcal disease, which causes infections like pneumonia and meningitis. Researchers will compare the safety and immune response of this new vaccine against currently available vaccines in 60…
Phase: PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 03, 2026 14:43 UTC
-
Can a Mom's shot shield her baby from RSV?
⭐️ VACCINE ⭐️ OngoingThis study aims to understand how well the ABRYSVO RSV vaccine works in the real world when given to pregnant women to protect their newborns. Researchers will look back at hospital records from Argentina and Uruguay to see if infants whose mothers got the vaccine were less likel…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 03, 2026 14:42 UTC
-
Data dive: does the annual COVID shot keep you out of the hospital?
⭐️ VACCINE ⭐️ OngoingThis study aims to measure how well the yearly updated Pfizer-BioNTech COVID-19 vaccine works in real-world conditions. Researchers will analyze existing, anonymous health insurance and state vaccination records for adults and children. They will compare health outcomes over six …
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 02, 2026 14:57 UTC
-
Scientists track RSV shot safety in over 1,000 seniors
⭐️ VACCINE ⭐️ OngoingThis study is monitoring the safety of the approved Abrysvo RSV vaccine in adults aged 60 and older in Japan. It will enroll about 1,100 participants who receive the vaccine as part of normal medical care. The main goal is to track any side effects, especially serious ones, in th…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 02, 2026 14:57 UTC
-
Massive study tracks 12,000 people for COVID vaccine side effects
⭐️ VACCINE ⭐️ OngoingThis study is monitoring the safety of the already-approved Pfizer COVID-19 vaccine in real-world use in Korea. It will follow 12,000 people who receive the vaccine as part of their normal healthcare, tracking any side effects they report for 28 days after each dose. The goal is …
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 01, 2026 14:43 UTC
-
Massive medicare data dive tests new pneumonia shot for seniors
⭐️ VACCINE ⭐️ OngoingThis study aims to see how well the Prevnar 20 vaccine works in real life to prevent serious lung infections and pneumonia in adults aged 65 and older. Researchers will analyze the anonymous health records of over 22 million people on Medicare, comparing those who got the vaccine…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 01, 2026 14:42 UTC
-
Pfizer tests new Super-Vaccine against pneumonia in chinese babies and adults
⭐️ VACCINE ⭐️ OngoingThis study is testing the safety of a new 20-strain pneumococcal vaccine (20vPnC) in healthy Chinese people of all ages, from infants to adults. The main goal is to see how well people tolerate the vaccine and to check for any side effects. Researchers will also measure the immun…
Phase: PHASE1 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:34 UTC
-
New vaccine aims to stop dangerous diarrhea germ
⭐️ VACCINE ⭐️ OngoingThis study is testing new versions of a vaccine designed to prevent severe diarrhea caused by the C. diff bacteria. It will involve about 936 healthy adults, primarily aged 65 and older, to see if the new vaccine formulas are safe and help the body build protective defenses as we…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:29 UTC
-
Real-World test: does the maternal RSV shot shield babies from hospitalization?
⭐️ VACCINE ⭐️ OngoingThis study is checking how well the ABRYSVO RSV vaccine works in the real world when given to pregnant people to protect their babies. Researchers will analyze existing medical records from Western Pennsylvania hospitals over several RSV seasons to see if vaccinated mothers' infa…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 25, 2026 14:08 UTC
-
Pfizer checks if Mom's shot shields newborns from dangerous RSV
⭐️ VACCINE ⭐️ OngoingThis study aims to see how well a vaccine (ABRYSVO) given to pregnant women works in the real world to protect their babies from being hospitalized with severe RSV lung infections. Researchers will look at the medical records of babies under 1 year old who were hospitalized in Au…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 24, 2026 12:02 UTC
-
Major trial tests first new lyme vaccine in decades
⭐️ VACCINE ⭐️ OngoingThis large study is testing whether a new vaccine called VLA15 can prevent Lyme disease in healthy people aged 5 and older. About 12,500 participants in high-risk areas of North America and Europe will receive either the vaccine or a placebo (saltwater shot) and be followed for u…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:19 UTC
-
Can a Mom's shot shield her baby from RSV?
⭐️ VACCINE ⭐️ OngoingThis study is checking how well the ABRYSVO RSV vaccine works when given to pregnant people to protect their babies after birth. Researchers will review the medical records of nearly 40,000 mothers and infants to compare health outcomes for babies whose mothers got the vaccine ve…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:17 UTC
-
Pfizer tracks infant safety for new pneumonia vaccine
⭐️ VACCINE ⭐️ OngoingThis study is monitoring the safety of the Prevenar 20 vaccine in real-world use in Japan. It is enrolling about 1,100 infants aged 2 to 6 months who are getting this vaccine for the first time. Researchers will track any side effects the infants experience after each of their fo…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:15 UTC
-
Major trial tests new shot to shield seniors from dangerous RSV
⭐️ VACCINE ⭐️ OngoingThis large, late-stage study is testing a new vaccine designed to protect adults aged 60 and older from serious lung infections caused by Respiratory Syncytial Virus (RSV). Over 38,000 participants will receive either the vaccine or a placebo and be followed for up to two years t…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 10, 2026 12:52 UTC
-
Pfizer tests Next-Gen shot against Pneumonia-Causing bacteria
⭐️ VACCINE ⭐️ OngoingThis study is testing a new vaccine designed to protect adults from pneumococcal diseases like pneumonia and meningitis. It will involve 558 adults in different age groups to see how safe the vaccine is and how well it triggers an immune response. Participants will receive a sing…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 04, 2026 15:30 UTC
-
First human test of Pfizer's new cancer drug begins
Disease control OngoingThis early-stage study is testing the safety and side effects of a new cancer drug called PF-08046032, both alone and in combination with another immunotherapy drug called sasanlimab. It involves a small group of adults with advanced lymphomas or solid tumors that have spread or …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 18:10 UTC
-
New hope for tough-to-treat breast cancer patients
Disease control OngoingThis study is testing whether adding the drug tucatinib to two standard breast cancer medications (trastuzumab and capecitabine) can help control advanced HER2-positive breast cancer that has worsened despite previous treatments. The trial enrolled 66 people with cancer that has …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 18:10 UTC
-
New Immune-Boosting drug tested in advanced cancer patients
Disease control OngoingThis study is testing a new immunotherapy drug called PF-06801591 in adults with advanced cancers that have spread or returned after standard treatments. The goal is to find a safe dose and see if the drug can help shrink tumors, particularly in non-small cell lung cancer. Partic…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 18:10 UTC
-
New drug duo aims to outsmart advanced prostate cancer
Disease control OngoingThis study is testing whether adding a drug called talazoparib to a standard prostate cancer drug (enzalutamide) works better than the standard drug alone. It is for men whose prostate cancer has spread and has specific DNA repair gene mutations. The main goal is to see if the co…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Korean study tracks Real-World safety of growth hormone treatment in children
Disease control OngoingThis study monitors the safety and effectiveness of Ngenla growth hormone treatment in Korean children with growth hormone deficiency. Researchers will follow 565 children and adolescents aged 3 and older for up to 6 years during routine medical care. The study aims to track side…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
One-Shot gene therapy aims to free hemophilia patients from constant treatments
Disease control OngoingThis study is testing whether a single gene therapy treatment can provide long-term control of Hemophilia B, a bleeding disorder. It follows men who received the therapy in an earlier trial to see how long the benefits last and monitors for any delayed side effects. A small group…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New pill combo tested for Tough-to-Treat breast cancer
Disease control OngoingThis study is testing the safety and effectiveness of two oral drugs, vepdegestrant and PF-07220060, taken together. It is for adults with a specific type of advanced or metastatic breast cancer that is no longer responding to standard hormone therapies. The goal is to see if thi…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Pfizer tracks Real-World results for eczema drug in japan
Disease control OngoingThis study is observing how well and how safely the medicine CIBINQO works for treating atopic dermatitis (eczema) in people under real-world medical care in Japan. It involves over 1,100 participants who are starting or continuing treatment with the commercially available drug. …
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Drug maker tracks Long-Term safety of new myeloma therapy
Disease control OngoingThis study is monitoring the long-term safety and effectiveness of the drug elranatamab in patients with relapsed and refractory multiple myeloma, a hard-to-treat blood cancer. It aims to collect real-world information on side effects, especially serious ones like cytokine releas…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis study is testing whether a daily pill called ritlecitinib can help restore skin color in adults with nonsegmental vitiligo. Over 1,500 participants will be randomly assigned to receive either one of two doses of the medicine or a placebo for one year, followed by another yea…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Drug safety watch: tracking side effects in Tough-to-Treat prostate cancer
Disease control OngoingThis study is monitoring the safety and side effects of the drug Talzenna in men with a specific, advanced form of prostate cancer. It involves men whose cancer has spread and continues to grow despite low hormone levels, and who have a specific genetic change (BRCA mutation). Th…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for PAH patients as pfizer tests novel treatment
Disease control OngoingThis study is testing a new medicine called PF-07868489 to see if it is safe and how it works in the body. First, healthy volunteers receive single doses to check safety. Then, people with pulmonary arterial hypertension (PAH) who are already on standard treatments receive the me…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Lung cancer patients get continued access to promising drug
Disease control OngoingThis study provides continued access to the lung cancer drug lorlatinib for patients who are already benefiting from it in previous Pfizer studies. It allows 76 participants with ALK-positive or ROS1-positive non-small cell lung cancer to keep receiving treatment while researcher…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New pill combo tested for Tough-to-Treat breast cancer
Disease control OngoingThis study is testing the safety and effectiveness of two oral drugs, vepdegestrant and samuraciclib, taken together daily. It is for adults with a specific type of advanced or spreading breast cancer that is no longer responding to standard hormonal therapies. The goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Drug maker tracks Real-World results for blood cancer treatment
Disease control OngoingThis study is monitoring the safety and real-world effectiveness of the drug Elranatamab in Korean patients with advanced multiple myeloma. It will enroll about 150 adults who have already received at least three prior treatments for their cancer. The goal is to gather informatio…
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
One-Shot gene therapy aims to free patients from lifelong bleeding disorder treatments
Disease control OngoingThis study is testing a one-time gene therapy for adult men with severe hemophilia B, a genetic disorder that prevents blood from clotting properly. The therapy aims to give the body long-lasting instructions to make its own clotting factor, potentially reducing or eliminating th…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New immune therapy tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing whether a new drug called elranatamab can help control multiple myeloma in people whose cancer has come back or stopped responding to several standard treatments. The drug works by guiding the body's own immune cells to find and attack the cancer cells. The …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill aims to tame severe eczema itch and rash
Disease control OngoingThis study is testing whether an experimental daily pill called PF-08049820 is safe and effective for adults with moderate to severe eczema (atopic dermatitis). About 200 participants will take either the study pill or a placebo (a pill with no medicine) for 12 weeks. Doctors wil…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Extended treatment study offers hope for chronic bowel disease patients
Disease control OngoingThis study continues testing etrasimod, a daily oral medication, for adults with moderate to severe ulcerative colitis. It follows participants from previous trials to evaluate long-term safety and effectiveness over up to two years. The goal is to help control this chronic infla…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Head-to-Head trial tests Next-Gen drug against standard for tough lung cancer
Disease control OngoingThis study tested whether a newer drug called lorlatinib works better than the standard drug crizotinib for people with advanced non-small cell lung cancer that has a specific genetic change (ALK-positive). The trial involved 296 adults who had not received any prior treatment fo…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Looking back at lung cancer Drug's Real-Life impact
Disease control OngoingThis study looks back at medical records to understand how well the oral medication lorlatinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) that has stopped responding to other treatments. Researchers are analyzing data from 35 patients who …
Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial tests new hope for men with Tough-to-Treat prostate cancer
Disease control OngoingThis large, late-stage study is testing whether adding a new drug called talazoparib to a standard prostate cancer treatment (enzalutamide) works better for controlling advanced disease. It involved over 1,000 men whose cancer had spread and stopped responding to standard hormone…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Three-Drug attack on deadly skin cancer enters final testing phase
Disease control OngoingThis study is testing if adding two oral drugs (encorafenib and binimetinib) to a standard immunotherapy (pembrolizumab) works better for people with advanced melanoma that has a specific BRAF gene mutation and hasn't been treated before. About 257 participants will be randomly a…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First human test of Pfizer's new cancer pill targets tough tumors
Disease control OngoingThis is an early safety study for a new oral medicine, PF-07985045, designed for people with advanced solid tumors that have a specific KRAS gene mutation. The study will test the medicine by itself and combined with other cancer treatments to find a safe dose and see how the bod…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for kids with severe bowel disease
Disease control OngoingThis study is testing an oral medication called tofacitinib to see if it can help children with moderate to severe ulcerative colitis achieve and maintain remission. It involves about 118 children aged 2 to 18 who haven't responded well to other treatments. The main goal is to se…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
First look: new cancer drug tested in china for Tough-to-Treat tumors
Disease control OngoingThis early-stage study aims to check the safety and understand how the body processes the drug tucatinib in a small group of Chinese patients. It includes people with advanced breast, stomach, or colorectal cancers that have a specific marker called HER2+ and have stopped respond…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Pfizer monitors new hemophilia drug for safety
Disease control OngoingThis study is checking the safety of a drug called Hympavzi in real-world use by patients with hemophilia A or B. It will follow about 50 patients for up to three years to see if any unexpected side effects occur. The main goal is to understand the drug's safety profile after it …
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Cancer patients get lifeline: continued access to treatment after trial ends
Disease control OngoingThis study provides continued access to crizotinib treatment for people with certain cancers who were already benefiting from the medication in previous Pfizer trials that are closing. It allows 27 eligible participants to keep receiving their treatment while researchers continue…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New pill challenges standard shot in advanced breast cancer fight
Disease control OngoingThis study is testing a new oral medicine called ARV-471 against the standard injection treatment, fulvestrant, for people with advanced breast cancer that has worsened despite prior hormone-based therapy. It involves about 624 participants who will be randomly assigned to receiv…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New cancer drug combo enters key testing phase
Disease control OngoingThis study is testing a new drug, PF-07220060, to see if it is safe and can help control advanced cancers. It will be given alone and in combination with other standard hormone therapies. The trial is for people with certain advanced solid tumors, including breast, prostate, and …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Gene therapy trial offers hope for boys with devastating muscle disease
Disease control OngoingThis study is testing whether a one-time gene therapy is safe and can help boys with Duchenne muscular dystrophy (DMD) maintain their ability to walk and move. About 99 boys, aged 4 to 7, will receive either the gene therapy or a placebo infusion. The main goal is to see if the t…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New injection challenges standard pill in major blood cancer trial
Disease control OngoingThis study aims to see if a new injectable drug called elranatamab works better than the standard oral medication lenalidomide for keeping multiple myeloma under control after a stem cell transplant. It involves 811 people recently diagnosed with this blood cancer who have alread…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Triple-Threat attack on advanced colon cancer
Disease control OngoingThis study is testing whether adding two targeted drugs (encorafenib and cetuximab) to an immunotherapy drug (pembrolizumab) works better than the immunotherapy alone for people with a specific type of advanced colorectal cancer that has spread. It is for adults whose cancer has …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for advanced breast cancer patients after standard treatment fails
Disease control OngoingThis study is testing whether adding an experimental drug called PF-07220060 to the standard hormone therapy fulvestrant works better than current treatment options for people with advanced breast cancer. It's for adults whose cancer has continued to grow despite previous treatme…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Cancer patients get continued access to promising treatment after trial ends
Disease control OngoingThis study allows patients with breast or head/neck cancer who benefited from palbociclib in previous Pfizer trials to continue receiving the medication. The main goal is to monitor the long-term safety of the treatment in these patients. Participants will be followed to track an…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Drug safety check for rare blood disorder
Disease control OngoingThis study aims to confirm the safety of the drug ATGAM for patients in Japan who have moderate to severe aplastic anemia, a rare condition where the body stops producing enough new blood cells. It will observe a small group of patients for 6 months to monitor for any side effect…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Pfizer tracks Real-World results of hair loss drug
Disease control OngoingThis study is monitoring the long-term safety and effectiveness of Litfulo capsules in people with alopecia areata (an autoimmune hair loss condition) during real-world use. It will follow about 500 patients who are starting the medication for the first time. The main goals are t…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Pfizer tracks safety of cancer drug in small patient group
Disease control OngoingThis study is monitoring the safety of the drug Talzenna in a small group of patients with advanced breast cancer that has returned or cannot be surgically removed. The patients have a specific genetic profile and have received prior chemotherapy. The main goal is to track any si…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Hair regrowth hope: major trial tests Long-Term alopecia pill
Disease control OngoingThis large, long-term study is testing the safety and effectiveness of an oral medication called PF-06651600 for people with alopecia areata, an autoimmune condition that causes hair loss. Over 1,000 adults and adolescents (age 12+) will receive the active drug to see if it helps…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New Two-Drug pill combo tested for Tough-to-Treat breast cancer
Disease control OngoingThis study is testing the safety and effectiveness of a new oral drug, ARV-471, when taken together with an existing cancer drug, abemaciclib. It is for adults with advanced or metastatic breast cancer that is hormone-sensitive but has stopped responding to previous treatments. T…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Tracking kids on growth hormone therapy for years to come
Disease control OngoingThis study is monitoring the long-term safety and growth effects of Ngenla, an approved treatment for children with growth hormone deficiency. It will follow children (boys under 15, girls under 13) who are starting Ngenla treatment for the first time. Researchers will track thei…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New pill combo aims to fight tough breast cancer
Disease control OngoingThis study is testing the safety and effectiveness of a new oral drug, ARV-471, when taken together with an existing cancer drug called ribociclib. It is for adults with advanced or metastatic breast cancer that is hormone-sensitive but has stopped responding to previous treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New Two-Pronged attack on Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a new drug called elranatamab in combination with other cancer therapies for people with multiple myeloma that has come back or stopped responding to several prior treatments. The main goals are to find the safest and most effective dose and to see if these …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Cancer drug under watch: Real-Life safety check for leukemia patients
Disease control OngoingThis study is monitoring how well the cancer drug Bosulif works and what side effects patients experience during routine treatment for chronic myeloid leukemia (CML) in Korea. It involves 600 adult patients who are newly diagnosed or have tried other treatments without success. R…
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphoma: trial tests Triple-Drug attack
Disease control OngoingThis study is testing the safety and effectiveness of a new three-medicine combination for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to prior treatments. The trial is for people who are not eligible for or do not want a stem cell …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
First patients test new pfizer cancer drug in early safety trial
Disease control OngoingThis is an early-stage study to test the safety and initial effects of a new drug called PF-08046037. It is being tested alone and in combination with another immunotherapy drug (sasanlimab) in people with advanced or spreading cancers, including lung, head and neck, skin, and pa…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Massive 99,000-Person study checks if paxlovid prevents severe COVID
Disease control OngoingThis study uses real-world health records from Ontario to see if the COVID-19 treatment Paxlovid helps prevent severe outcomes like hospitalization or death. It compares the experiences of adults who received the drug at a pharmacy to those who did not, tracking their health for …
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for advanced breast cancer: experimental drug combo enters final testing phase
Disease control OngoingThis study is testing whether a new drug called vepdegestrant, when combined with palbociclib, works better than the current standard treatment (letrozole plus palbociclib) for advanced breast cancer. It's for adults with a specific type of breast cancer (estrogen receptor positi…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 09, 2026 14:22 UTC
-
New bladder cancer combo aims to stop tumors from coming back
Disease control OngoingThis large, late-stage study is testing whether adding a new immunotherapy drug called sasanlimab to the standard BCG treatment works better than BCG alone for people with high-risk, early-stage bladder cancer. The main goal is to see if the combination helps keep the cancer from…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 02, 2026 15:20 UTC
-
Massive health record study tests if new vaccine can stop pneumonia
Prevention OngoingThis study aims to find out how well the PCV20 vaccine prevents pneumonia and other lung infections in adults who are at higher risk. Researchers will use existing health records from over 800,000 Kaiser Permanente members in Southern California, comparing infection rates between…
Sponsor: Pfizer • Aim: Prevention
Last updated Apr 02, 2026 14:56 UTC
-
Tracking migraine relief: does this pill work the same every time?
Symptom relief OngoingThis study aims to understand how consistently a migraine medication called rimegepant works for people in real life. It will follow 250 adults in the UK who already have a prescription for this drug to treat their migraine attacks. Participants will report their symptoms and med…
Sponsor: Pfizer • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC
-
New nasal spray aims to stop migraine pain in two hours
Symptom relief TerminatedThis study aimed to test if a nasal spray called zavegepant could quickly relieve migraine pain. Adults with a history of migraines would have used the spray at home during up to four attacks to see if it made the pain go away within two hours. The trial was withdrawn by the spon…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Mar 18, 2026 14:40 UTC
-
Massive data dive: how europe treats blood clots in cancer patients
Knowledge-focused OngoingThis study looks back at existing medical records to understand how blood clots are treated in people with cancer across Europe. Researchers are analyzing data from thousands of patients to see which blood-thinning medications work best, what side effects occur, and how much trea…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:48 UTC
-
Pfizer tests drug interaction in healthy volunteers
Knowledge-focused OngoingThis early-stage study aims to understand how a new medicine (PF-08049820) is processed by the body when taken with a common stomach acid drug (rabeprazole). It involves 18 healthy Chinese adults who will take both medicines separately and together. Researchers will measure drug …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Pfizer tests new eczema pill in first human safety trial
Knowledge-focused OngoingThis is an early safety study for a new oral medicine, PF-08049820, being developed to treat moderate-to-severe eczema (atopic dermatitis). The main goal is to check if the drug is safe and well-tolerated in healthy adult volunteers. Researchers will also measure how the body abs…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
Real-World watch: tracking RSV vaccine safety for moms and newborns
Knowledge-focused OngoingThis study is monitoring the safety of the Abrysvo RSV vaccine in pregnant women and their infants under real-world conditions in Japan. It involves 497 pregnant women who received the vaccine after it became available. Researchers are tracking any side effects in the mothers for…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
Scientists track Real-World journey of rare heart disease patients
Knowledge-focused OngoingThis study aims to understand how a rare heart condition called ATTR-CM is managed in real-world medical practice. Researchers will observe and collect data from about 350 patients in Taiwan, Hong Kong, and Malaysia who have already been diagnosed. The study does not test any new…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Pfizer digs into data: can its vaccine stop long COVID?
Knowledge-focused OngoingThis study uses existing health insurance and state vaccination records to answer two main questions. First, it aims to measure how well the Pfizer-BioNTech COVID-19 vaccine prevents Long COVID symptoms. Second, it seeks to understand the characteristics of people who are getting…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Pfizer tracks Real-World side effects of its COVID shot in korea
Knowledge-focused OngoingThis study is monitoring the safety of the already-approved Comirnaty COVID-19 vaccine in real-world use in Korea. It will track side effects in 660 Korean people who receive the vaccine as part of their normal medical care. The goal is to gather more safety information after the…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
Researchers track Real-World outcomes for patients with Hard-to-Treat blood cancer
Knowledge-focused OngoingThis observational study aims to understand how doctors in Italy currently treat patients with advanced multiple myeloma that has stopped responding to standard medications. Researchers will collect existing medical records from about 250 adult patients to analyze treatment appro…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Pfizer asks: how bad is your COVID or flu really?
Knowledge-focused OngoingThis study aims to understand how COVID-19 and influenza symptoms affect people's daily lives and health over time. It will follow 999 adults in the US who test positive for either virus and report having symptoms. Participants will fill out surveys about their symptoms, work, an…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Looking back to find the safest blood thinner for High-Risk hearts
Knowledge-focused OngoingThis study analyzed past medical records to understand how doctors treat patients with an irregular heartbeat (atrial fibrillation) who also have a high risk of stomach bleeding. Researchers looked at which blood thinners were prescribed and compared how often patients experience…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Pfizer tests new medicine in healthy volunteers for first time
Knowledge-focused OngoingThis is Pfizer's first human study of a new medicine called PF-07999415. It aims to check if a single injection is safe and how the body processes it in 32 healthy adults aged 18-65. Participants stay in a medical facility for 2 weeks after their injection for close monitoring, t…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test new skin Drug's hidden effects on birth control and blood thinners
Knowledge-focused OngoingThis early-stage study aims to understand how an experimental atopic dermatitis (eczema) medication called PF-08049820 affects how the body processes three common drugs: birth control pills, a sedative (midazolam), and a blood thinner (dabigatran). Researchers will enroll 16 heal…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Swedish cancer registry tracks 1,500 patients on common treatment
Knowledge-focused OngoingThis study aims to understand how Swedish patients with advanced breast cancer are using the drug palbociclib in everyday medical care. It will observe about 1,500 adult patients who have been prescribed this medication, tracking how long they stay on treatment and their health o…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Paxlovid pill test halted before it began
Knowledge-focused TerminatedThis study aimed to see if a new, combined tablet form of the COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) works the same way in the body as the original separate pills. It planned to test this in a small group of healthy adults by measuring drug levels in their blood. Th…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Pfizer tests new heart pill on healthy volunteers
Knowledge-focused OngoingThis early-stage study aims to understand how a potential new heart failure medicine called PF-07328948 is processed by the body and whether it's safe to take. Ten healthy Chinese adults will take the oral medication daily for one week while researchers monitor their health. The …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Researchers check how well the RSV shot protects seniors over time
Knowledge-focused OngoingThis study aims to understand how well the ABRYSVO vaccine works in the real world to prevent severe RSV infections in adults aged 60 and older. Researchers will analyze existing health records over several years to see how effective the vaccine is at preventing hospitalizations …
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
Safety check: does a migraine drug affect pregnancy?
Knowledge-focused OngoingThis study looks back at medical records to see if taking the migraine medication rimegepant during pregnancy is linked to any risks for the mother or baby. It compares pregnancy outcomes in three groups: women with migraines who took rimegepant, women with migraines who took oth…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC
-
Scientists test drug mix in healthy volunteers
Knowledge-focused OngoingThis study aims to understand how a common antifungal drug (itraconazole) changes how the body processes an experimental medicine called PF-07248144. It involves 12 healthy adults who will take the experimental medicine alone and then with itraconazole. Researchers will measure d…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC
-
Researchers track Real-Life results of popular breast cancer drug
Knowledge-focused OngoingThis study looks at how the breast cancer drug palbociclib is actually used in everyday medical practice and what results patients experience. Researchers will analyze anonymous medical records of adults with advanced hormone-positive breast cancer who started treatment between 2…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:08 UTC